Shots: Foghorn will receive an upfront, development, regulatory and commercial milestones totaling up to $425M as well as royalties on sales of any approved therapy emerges from the collaboration Merck […]readmore
Tags : Oncology Therapies
Shots: Cipla expands partnership with Roche to improve access to key oncology medicines which include Herclon (trastuzumab), Avastin (bevacizumab) and Ristova (rituximab) in India. Cipla will be responsible for the […]readmore
Shots: BMS to receive $65M up front, including $15M equity investment and is eligible to receive $3B as license fees, discovery, development, regulatory and commercial milestones, in addition to royalty […]readmore